Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

SciClone Pharma to Begin Developing Oral Mucositis Treatment in China

publication date: Dec 21, 2015
SciClone Pharma will develop a treatment for oral mucositis for the Greater China market. SciClone acquired China rights to the drug, SGX942, from Soligenix of the US in 2013 in exchange for SciClone's library of China clinical and regulatory data, produced by an oral mucositis treatment it abandoned. Last week, Solgenix reported positive Phase II data for SGX942 in a US trial, prompting SciClone to begin China development. SciClone is headquartered in California, but most of its operations are centered in China. More details....

Stock Symbol: (NSDQ: SCLN) (OTC: SNGX)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital